Company Information

  

Address: IM NEUENHEIMER FELD 582, 69120  
City: HEIDELBERG 
State:  
Zip Code: 000000 
Telephone: 49-6221-65307 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Our product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK cells, and T cells. Our proprietary, next-generation bispecific antibodies, which we call TandAbs because of their tandem antibody structure, are designed to direct and establish a bridge between either NK cells or T cells and cancer cells. Our TandAbs have the ability to bring NK cells or T cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
There's no share overview data.

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-64.58Total Liab/Total Assets0.27
Net Inc/Total Assets-0.70Total Liab/Inv Cap0.36
Net Inc/Inv Cap-0.93Total Liab/Comm Equity24.74
Pretax Inc/Net Sales-15.04Interest Coverage RatioNA
Net Inc/Net Sales-15.03Curr Debt/Equity0.10
Cash Flow/Net Sales-12.71LTD/Equity0.13
SG&A/NetSales3.87Total Debt/Equity0.23
Asset Utilization   Liquidity  
Net Receivables Turnover1.30Quick Ratio5.57
Inventory TurnoverNACurrent Ratio5.60
Inventory Day SalesNANet Rec/Curr Assets0.03
Net Sales/Work Cap0.06Inv/Curr Assets0.01
Net Sales/PP&E1.81  

Income Statement (Millions)

  12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Revenues(Net Sales) 2.41 6.66 8.22 4.09
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 9.34 8.63 7.49 2.38
Operating Income -32.73 -33.80 -23.19 -9.90
Interest Exp NA NA NA NA
Pretax Income -36.32 -34.04 -21.99 -0.51
Other Income NA NA NA NA
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -36.29 -33.98 -21.99 -0.31

Balance Sheet (Millions)

Assets 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Cash & Short Term Investments 47.84 37.35 83.36 48.07
Receivables - Total 1.32 2.38 0.99 1.14
Inventories - Total 0.29 0.21 0.25 0.24
Total Current Assets 50.41 50.48 85.10 49.45
Net Property, Plant & Equipment 1.34 0.87 0.99 1.18
Total Assets 51.83 51.41 86.17 50.71
Liabilities        
Accounts Payable 5.02 5.61 4.83 4.55
Debt in Current Liabilities 3.70 1.03 1.60 0.00
Total Current Liabilities 9.00 6.72 9.72 7.53
Long-Term Debt 4.91 3.82 3.37 4.71
Total Liabilities 13.90 10.54 13.09 12.24
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.56 0.35 0.36 0.29
Retained Earnings -219.35 -160.79 -130.61 -120.99
Treasury Stock NA NA NA NA
Total Stockholders' Equity 37.92 40.87 73.08 38.47
Total Liabilities and Stockholders' Equity 51.82 51.41 86.17 50.71

Cash Flow Summary (Millions)

Categories 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Cash Provided by Operating Activities -30.68 -33.89 -20.14 -12.76
Net Cash Provided by Investing Activities 9.67 -9.65 -0.30 -0.36
Net Cash Provided by Financing Activities 28.58 -0.25 58.12 54.32

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20137.01-35.96--
12/20144.09-0.31--
12/20158.22-21.99--
12/20166.66-33.98--
12/20172.41-36.29--
Growth Rates-23.40----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/184925,64641.11




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.